(Q44060104)

English

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

parkinsonian syndrome

1 reference

based on heuristic

inferred from title

4

object named as

Anthony Lang

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3

object named as

Stanley Fahn

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Charles Warren Olanow

7

object named as

C Warren Olanow

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

10

object named as

Karl Kieburtz

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Caroline M Tanner

9

object named as

Caroline Tanner

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Parkinson Study Group

12

object named as

Parkinson Study Group

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

object named as

Ira Shoulson

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

2

object named as

David Oakes

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Peter A. Lewitt

6

object named as

Peter LeWitt

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

J William Langston

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

John B Penney

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Alice Rudolph

11

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Annals of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

604-612

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Mortality in people taking selegiline: observational study

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Selegiline and mortality in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Freezing of gait in PD: prospective assessment in the DATATOP cohort

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

DATATOP: A decade of neuroprotective inquiry

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

TechSight. Imaging. A molecular map for neurodegeneration

1 reference

https://api.crossref.org/works/10.1002%2FANA.10191

21 January 2018

Identifiers

10.1002/ANA.10191

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

release_q25f3fo3vfhsfjaipbrscewlmy

1 reference

https://api.fatcat.wiki/v0/release/q25f3fo3vfhsfjaipbrscewlmy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44060104&oldid=2106128836"